awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26752780-048CA576-5F40-438F-BDE8-4EDF54C9EB30
Q26752780-048CA576-5F40-438F-BDE8-4EDF54C9EB30
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26752780-048CA576-5F40-438F-BDE8-4EDF54C9EB30
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
P2860
Q26752780-048CA576-5F40-438F-BDE8-4EDF54C9EB30
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26752780-048CA576-5F40-438F-BDE8-4EDF54C9EB30
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b90bf2e3577d7fd6c47ca695cc452f621c8f9671
P2860
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial